We’ve shortlisted four major biotech stocks with upcoming news in April related to FDA decisions. Where will the news take GW Pharmaceuticals (NASDAQ:GWPH), FibroGen (NASDAQ:FGEN), Heron Therapeutics (NASDAQ:HRTX), and Assembly Biosciences (NASDAQ:ASMB)?
Biotech Stocks: GW Pharmaceuticals Phase 3 Trial Data for Epidiolex
In the next few weeks, GW Pharmaceuticals will announce phase 3 trial results for Epidiolex use in treating patients with tuberous sclerosis (TSC) associated uncontrollable seizures.
Epidiolex is a cannabis-based drug for two treatment-resistant forms of early-onset epilepsy. The success of the clinical trial will bring an influx of 25,000 patients to an existing pool of 35,440 currently eligible for the treatment. GWPH stock has outperformed the broader market in 2019 with a gain of over 65% year-to-date.
Biotech Stocks: FibroGen’s Big News
This April, FibroGen is scheduled to report the results of its phase 2 trial with pamrevlumab as treatment for non-ambulatory Duchenne muscular dystrophy (DMD). FibroGen’s roxadustat has already been approved in China for kidney-disease-associated anemia treatment, and the company is also gearing up to submit the same application in the US later in the year.
FGEN stock is up about 28% so far in 2019 and up about 1% to $54.93 in Wednesday’s session.
>> Google’s Stadia: Is the Online Gaming Revolution Nearing?
Biotech Stocks: Heron Therapeutics’ HTX-011
Heron Therapeutics is in the quest to come up with a non-addictive post-surgical pain medication. The company’s HTX-011 has been granted a priority review by the FDA with the authority’s decision expected by the end of April.
HRTX stock currently trades at $25.78, up 0.81%, on the NASDAQ. The stock has fallen over 40% from its mid-June high of $42.90.
Biotech Stocks: Assembly Biosciences’ Presentation at the EASL
Assembly Biosciences will be presenting at the European Association for Study of the Liver (EASL) on April 13th, 2019. How the presentation goes may result in stock movement for the company.
The company has been granted the opportunity to present its 6-month data from an ongoing phase 2 clinical trial of its proprietary ABI-H0731 for treatment of the Hepatitis B virus (HBV). ASMB stock has corrected over 60% from its 52-week high of $52.32.
What biotech stocks are you interested in?
Featured image: DepositPhotos © motorolka
